Latest NS5 Stories
LONDON, March 17, 2015 /PRNewswire/ -- Report DetailsHepatitis C treatments - your guide to medical needs, R&D trends and future drug revenuesDiscover the future of treating
- Major regulatory milestone achieved toward approval in the European Union NORTH CHICAGO, Ill., Nov.
A study reveals how daclatasvir targets one of its proteins and causes the fastest viral decline ever seen with anti-HCV drugs – within 12 hours of treatment.
Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer.
- Emitting flashes of light; glittering.